Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Regeneron Pharmaceuticals Inc (REGN) reports robust financial performance with a 10% revenue increase and unveils new ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the ...

Linvoseltamab (BCMAxCD3 ... Factor XI for anticoagulation: Regeneron’s two-pronged approach to anticoagulation is being evaluated for its potential to control thombosis while minimizing bleeding ...

Regeneron collaborates with Truveta and leading American ... with a potential BLA submission to follow. Linvoseltamab (BCMAxCD3) for multiple myeloma: Linvoseltamab has potential to be the ...

Regeneron’s pipeline is a key differentiator, particularly in oncology, with significant progress in submissions for linvoseltamab and odronextamab, and positive data for Libtayo in adjuvant CSCC.

Regeneron management has indicated several ... The company also revealed preliminary data on linvoseltamab combined with Dupixent in a patient with severe food allergies, showing a reduction ...

Regulatory setbacks, including the FDA’s complete response letter for linvoseltamab, further contributed to investor concerns. Analysts' consensus rating on Regeneron Pharmaceuticals stock is ...

Regeneron recently announced that the primary ... The FDA issued a CRL for the BLA for linvoseltamab, a bispecific antibody targeting BCMA and CD3, in R/R multiple myeloma that has progressed ...